Fish oil remains one of the most popular supplements in the United States, yet the strongest new evidence of the past several years has cut against taking it for heart protection if you are healthy. The VITAL trial found no significant reduction in major cardiovascular events among 25,871 adults taking 1 gram of omega-3 daily. The UK Biobank cohort study published in 2024 in BMJ Medicine followed more than 415,000 people and found regular fish oil supplement use was associated with a modestly lower risk of atrial fibrillation progression and death only among people who already had cardiovascular disease — and, strikingly, with a higher risk of developing atrial fibrillation among those who did not. The prescription-strength exception, icosapent ethyl, is the one product with a positive large trial behind it.
This article publishes information, not medical advice. If you have existing heart disease, elevated triglycerides or take an anticoagulant, supplement decisions belong with your cardiologist, not a marketing shelf.
What are omega-3s supposed to do?
EPA and DHA, the long-chain omega-3 fatty acids in fish, incorporate into cell membranes and generate signaling molecules that modestly lower triglycerides, slightly reduce blood pressure and have anti-inflammatory effects in laboratory models. The Recommended Dietary Allowance the National Academies sets for omega-3s — about 1.1 grams daily for women and 1.6 grams for men — covers only the minimum to prevent deficiency, per the NIH Office of Dietary Supplements, not a dose proven to prevent disease. Fatty fish twice a week delivers far more than a standard capsule and comes bundled with protein and selenium.
Why did the prevention trials fail?
Three mechanisms explain the gap between early promise and later nulls. First, the oldest trials compared fish oil against no treatment in populations that ate little fish; modern trials in well-nourished populations start from a high baseline, leaving the capsules little to add. Second, doses moved less than assumed: 1 gram of mixed EPA-DHA drops triglycerides only modestly, and triglyceride lowering itself has a weaker link to event reduction than LDL lowering. Third, two large modern trials — STRENGTH (13,078 participants, 4 grams of EPA-DHA daily, results reported in 2020) and several others — found no benefit, while one trial of purified EPA did.
Why is one prescription product different?
The REDUCE-IT trial, published in the New England Journal of Medicine in November 2018, enrolled 8,179 patients with elevated triglycerides on statins and randomized them to 4 grams daily of icosapent ethyl — a synthetic, highly purified EPA — or mineral oil placebo. Cardiovascular events fell by about 25 percent. The result is real but narrower than headlines suggested: it applies to that drug, that dose, that population, and its placebo arm raised questions some researchers still debate. Icosapent ethyl is prescription-only; it is not the fish oil on a supermarket shelf, and the 2023 CLEAR Outcomes trial of bempedoic acid has since further crowded the prevention field.
Related stories: Vitamin D Supplements: What the Evidence Actually Supports — and What Marketing Oversells · Do Multivitamins Work? What the USPSTF and Large Cohorts Concluded.
What about bleeding and atrial fibrillation?
The safety ledger has grown longer as doses rose. Meta-analyses of randomized trials, including data reviewed around the STRENGTH and REDUCE-IT era, show dose-related increases in atrial fibrillation risk at 1 gram daily and above, concentrated in people with existing cardiac risk. Bleeding risk rises mainly at higher doses and in combination with anticoagulants or antiplatelet drugs — a live concern for the many adults who combine fish oil with low-dose aspirin. Fishy burps and reflux are trivial by comparison, but they drive most discontinuation.
Does the form or the label matter?
Supplements use triglyceride, ethyl ester or re-esterified triglyceride forms; absorption differences exist but are second-order next to whether you take capsules with a fat-containing meal. The Supplement Facts label lists total fish oil, then EPA and DHA separately — a "1,000 mg fish oil" capsule often carries only 300 mg of combined EPA and DHA, which matters because trials dosed by those two molecules, not by oil. Products certified by USP or NSF have been independently assayed for content and oxidation, a real consideration since omega-3 oils are prone to rancidity.
What about pregnancy and the brain?
Two omega-3 uses sit outside the heart story and deserve separate math. In pregnancy, DHA supports fetal brain and retinal development, and professional societies recommend roughly 200 mg of DHA daily for pregnant people, with low-dose supplementation generally considered appropriate when fish intake is low. Trials of omega-3s for preventing postpartum depression have been disappointing, but pregnancy-specific DHA guidance stands on developmental evidence rather than event reduction. For cognition in older adults, the picture mirrors the heart story: observational studies of fish eaters look good, while randomized trials of capsules in community-dwelling older adults have shown no meaningful slowing of cognitive decline, per the NIH-supported trials of the past decade. One documented exception exists in very early life — preterm infants given DHA-enriched nutrition in some trials showed small developmental advantages — which is a neonatology decision, not a consumer purchase.
Cost is worth naming too. A quality-tested fish oil supplement runs a few dollars a month; two weekly servings of canned salmon or sardines cost about the same and replace protein at the same time. When a null-prevention supplement competes against a food that meets the same intake goal, the comparison is not close.
What should a reader do differently?
For prevention in a healthy person, eat fish rather than capsule it: two servings of fatty fish weekly meets advice from the American Heart Association's dietary guidance, and food sources carry none of the atrial fibrillation signal seen in supplement cohorts. If you already have cardiovascular disease or triglycerides above 500 mg/dL, ask your clinician specifically about icosapent ethyl rather than assuming over-the-counter fish oil is equivalent. Review any capsule you take with your pharmacist alongside anticoagulants, and watch the pipeline: large trials of EPA formulations in new populations and of omega-3 index-guided dosing are still reading out, so this evidence base is still moving.
For more context, read Do Multivitamins Work? What the USPSTF and Large Cohorts Concluded.
For more context, read supplement drug interactions.
For more context, read vitamin d supplements.